title: Seronegative myasthenia gravis with bladder dysfunction.
authors.forename: I
authors.initials: I
authors.lastname: Marouani
authors.forename: I
authors.initials: I
authors.lastname: Kraoua
authors.forename: H
authors.initials: H
authors.lastname: Benrhouma
authors.forename: I
authors.initials: I
authors.lastname: Rebai
authors.forename: A
authors.initials: A
authors.lastname: Rouissi
authors.forename: S
authors.initials: S
authors.lastname: Koubaa
authors.forename: I
authors.initials: I
authors.lastname: Turki
authors.forename: C
authors.initials: C
authors.lastname: Dziri
authors.forename: N
authors.initials: N
authors.lastname: Gouider-Khouja
mesh_terms: D000200:Action Potentials / Q000502:physiology; D000293:Adolescent; D001763:Blepharoptosis / Q000209:etiology; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D004576:Electromyography; D005260:Female; D006801:Humans; D009157:Myasthenia Gravis / Q000150:complications* / Q000276:immunology; D009801:Oculomotor Muscles / Q000502:physiology; D011729:Pyridostigmine Bromide / Q000008:administration & dosage / Q000627:therapeutic use; D013934:Thymectomy; D001750:Urinary Bladder, Neurogenic / Q000188:drug therapy / Q000209:etiology* / Q000276:immunology; D014563:Urodynamics / Q000187:drug effects / Q000502:physiology
chemical_list: D002800:Cholinesterase Inhibitors; D011729:Pyridostigmine Bromide